Live

FierceBiotechGilead loosens ties to Arcus after TIGIT dream finally ends in phase 3 failure FierceBiotechWith $50M from Flagship Pioneering, Serif strives to write new chapter for DNA medicines Lonza NewsFDA-backed drug project tests modeling to reduce some human studies - Stock Titan Thermo FisherSaladax Biomedical and Thermo Fisher Scientific Partner on Global Distribution of Drug Monitoring Assays - Clinical Lab Products Thermo FisherTD Cowen Lowers Thermo Fisher (TMO) Price Target, Keeps Buy Rating - Yahoo Finance Lonza NewsLonza Group AG stock (CH0013841017): Is its biopharma contract model resilient enough for new growth - AD HOC NEWS FierceBiotechReplimmune ramps up layoffs to cover 60% of workforce amid ongoing fallout of FDA rejection 10x Genomics Blog10x Genomics debuts Atera, a new platform to redefine how biology is measured and understood at AACR 2026 - SelectScience IlluminaClinical Genomic Market: Growth and Outlook Driven by Illumina, - openPR.com Thermo FisherAssessing Thermo Fisher Scientific (TMO) Valuation After New PCR Launch And Data Partnerships - simplywall.st Curiosis Inc.Working capital per share of Curiosis, Inc. – KRX:494120 - TradingView WatersWaters Corporation Schedules First Quarter 2026 Earnings Conference Call - ChartMill

Cell Nov 25, 2025

<em>De novo</em> design of a peptide modulator to reverse sodium channel dysfunction linked to cardiac arrhythmias and epilepsy

Publication date: 30 October 2025Source: Cell, Volume 188, Issue 22Author(s): Ryan Mahling, Bence Hegyi, Erin R. Cullen, Timothy M. Cho, Aaron R. Rodriques, Luc...

Publication date: 30 October 2025Source: Cell, Volume 188, Issue 22Author(s): Ryan Mahling, Bence Hegyi, Erin R. Cullen, Timothy M. Cho, Aaron R. Rodriques, Lucile Fossier, Marc Yehya, Lin Yang, Bi-Xing Chen, Alexander N. Katchman, Nourdine Chakouri, Ruiping Ji, Elaine Y. Wan, Jared Kushner, Steven O. Marx, Sergey Ovchinnikov, Christopher D. Makinson, Donald M. Bers, Manu Ben-Johny